UBS Initiates Coverage on Longs Drug Stores (LDG) with a Buy
More News related to LDG
- Longs Drug Stores to Continue to Service Medi-Cal Patients
- Longs Drug Stores Opens New Store in Carpinteria
- Longs Drug Stores (LDG) Reports Preliminary May Retail Drug Store Sales
- Longs Reports Preliminary May Retail Drug Store Sales
- Longs Drug Stores Corporation Announced at Its Annual Meeting of Stockholders
UBS initiates coverage on Longs Drug Stores (NYSE: LDG) with a Buy. Price target $55.
Longs Drug Stores Corporation operates in two business segments: retail drug stores, and through its RxAmerica subsidiary, pharmacy benefit services.
Related Categories
New CoverageStocks Mentioned
-0.12Related Entities
Sign up for StreetInsider Free!
Recieve full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
